Search
Washington, DC (June 17, 2022) – Shabbir Safdar, executive director of The Partnership for Safe Medicines, released the following statement today: “The U.S. Senate Committee on Health, Education, Labor & Pensions’ 15-7 vote against Senator Sanders’ foreign drug importation amendment to S. 4348, the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act, is a step in the right…
Read More
Consumption of undeclared diclofenac could result in serious adverse events that include cardiovascular, gastrointestinal, renal, and anaphylaxis in patients taking concomitant NSAIDs and/or anticoagulants, in those who have allergies to diclofenac, or those with underlying illnesses. Consumption of undeclared dexamethasone may lead to severe and serious adverse events such as adrenal suppression, a disorder in which the adrenal glands do not produce enough hormones, and adverse consequences can range from limited adverse consequences to death.
Read MoreWashington, D.C. (Updated June 13, 2022) – Shabbir Imber Safdar, executive director of the Partnership for Safe Medicines, released the following statement in advance of the Senate HELP Committee’s June 14th Executive Session. “The amendments offered to include foreign drug importation in S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act, are a dangerous step toward opening…
Read More
So, what does all of this have to do with importing drugs from a friendly nation like Canada? The simple, inarguable fact is that, once we open up our drug supply, we can no longer ensure the safety of the products in it.
Read More
Instead of wasting time and money on dangerous and faulty importation proposals, Congress should encourage the FDA to speed up the drug approval process and reduce the cost of program and application fees for future drug development. In 2022, the application fee for a human drug application will cost $1.6 million for drugs that don’t require clinical data and $3.1 million for medicines that do need clinical data.
Read More
In this week’s news: A San Diego doctor pays for smuggling hydroxychloroquine to sell fake $4,000 COVID treatment kits; the British Medical Journal writes about black market sales of molnupiravir; Canadians warn about fake Xanax made with flualprazolam; and 14 more stories in 11 states.
Read More
While working to find a way to provide relief to patients at the pharmacy counter, American politicians again look to the idea of drug importation as a possible solution. Looking at all the evidence, the Partnership for Safe Medicines believes such plans will not only make no difference in reducing patient out-of-pocket costs, but will open the door to counterfeit…
Read MoreWatch our new ad: “Congress: Don’t invite global drug counterfeiters to the U.S. Drug Supply” As the pandemic upended our daily lives, illegally-imported counterfeit products flooded into our communities. Criminals all over the world moved quickly to exploit fear and take advantage of disrupted supply lines in March 2020. Americans were-and continue to be-deluged in fake COVID-19 treatments, fake home…
Read More
PSM holds its 2022 congressional briefing. A study of FDA enforcement actions underscores the real threat of fake drugs; a New York pharmacy-owner who allegedly sold fake HIV drugs is sentenced in a different crime; large amphetamine pill seizures in Montreal and Jordan; and stories relating to pressed counterfeit pills in 16 states.
Read More
Trafficking pharmaceuticals or illicit drugs violates Facebook’s community guidelines, but drug dealers are advertising them on Facebook anyway–even after they’ve been reported. Watch to learn more.
Read More